Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...